Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NELL2-interacting cell ontogeny regulator 1 (NICOL1) is a protein-coding gene that produces an mRNA-binding protein predicted to play roles in the stabilization of target mRNAs, including those involved in the extracellular matrix and smooth muscle (e.g., SERPINE1, ACTA2, CCN2, COL4A1). It acts as a testis-derived lumicrine signal, crucial for promoting epididymal differentiation and sperm maturation. NICOL1 is believed to function primarily in the perinuclear region of the cytoplasm and may also be secreted extracellularly. While mutations or deletions involving NICOL1 have been associated with rare syndromes such as Wolf-Hirschhorn syndrome and renal fibrosis, there is currently no evidence that it is a direct target for any known therapeutic drugs or acts as a classic receptor, enzyme, transporter, or ion channel. The protein is also referenced in animal models for its role in growth regulation and spermatogenesis. NICOL1's expression and function are distinct from NELL2, its interacting protein—NELL2 itself has broader roles, including neuronal survival and potentially in cancer progression via E2F1 regulation, but these roles do not directly extend to NICOL1 based on current evidence. NICOL1 is not currently a therapeutic target in the conventional sense (i.e., not a receptor, enzyme, transporter, or druggable protein), and there are no approved or investigational drugs that interact with it or utilize it as a pharmacodynamic or predictive biomarker.
Not established for any therapeutic drugs; NICOL1 binds to mRNA 3'-UTRs to stabilize specific mRNAs (e.g., SERPINE1, ACTA2) and to prevent degradation, thus possibly regulating target protein expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NELL2-interacting cell ontogeny regulator 1 (NICOL1).